Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

Anifrolumab effectively improved lupus headaches in a patient unresponsive to other treatments.

Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.

GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.

Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Dupilumab users have a higher risk of developing alopecia areata.

Dupilumab significantly improved a 5-year-old girl's prurigo nodularis without side effects.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

A woman with bullous pemphigoid had an allergic reaction to azathioprine, but got better with alternative treatments.

Dupilumab may help regrow hair in people with severe alopecia.

Dupilumab treatment reduces Th2-related markers and helps hair growth in alopecia areata, showing Th2's role in the condition.

Dupilumab can cause rare side effects like a rash on the face and neck.

Dupilumab effectively treats various inflammatory skin diseases beyond its initial use for atopic dermatitis.

Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.

Granzyme B is important in autoimmune skin diseases and could be a new treatment target.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Abrocitinib may effectively treat stubborn alopecia universalis.

Ocrelizumab may cause delayed hair loss in some patients.

Dupilumab effectively improves skin conditions, reduces symptoms, and enhances quality of life in certain dermatological issues.

Ritlecitinib is generally safe for alopecia areata patients over 72 months.

Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.

Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.

Intensive immunosuppression can reduce relapse rates in multiple sclerosis patients, despite some side effects.

Deuruxolitinib is approved to treat severe alopecia areata in adults.

Amotosalen-treated donor T-cells can prevent late CMV infection after bone marrow transplants.